CDER’s Plan For Prioritizing Safety Issues Leaves Industry Wanting More Details
Executive Summary
Pharma/biotech stakeholders push FDA for more clarity on its plans to pilot test a new system for classifying significant drug safety issues and timelines for agency action. Questions about public disclosure of FDA’s classification decisions and handling of safety issues across indications also are raised in industry comments on a draft guidance.
You may also be interested in...
CDER To Pilot Test New Framework For Classifying Drug Safety Issues
A recent draft guidance spells out the agency’s proposed approach to classifying significant post-marketing safety concerns for “standard,” “priority” or “emergency” handling. After pilot testing the framework over the next year, CDER intends to develop milestones for regulatory action on safety issues, similar to NDA/BLA action dates under PDUFA.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.